BROAD STREET ANGELS INVESTS IN SENECA THERAPEUTICS WITH BREAKTHROUGH BIOTECHNOLOGY TO TREAT CANCER – Broad Street Angels
Summary
“Referred by one of our members, Seneca Therapeutics has generated a significant BSA investment that will help the company conduct its next phase of research and further establish this region as a bioscience hub,” said Rosenthal. Dr. Paul Hallenbeck the Founder, President and CSO of Seneca, is a multiple award winning, serial entrepreneur, with 27 years in the biotechnology industry and expertise in all phases of cancer immuno-therapeutics R&D. “We are thrilled to obtain this investment so close to home from the Broad Street Angels as we establish our efficacy in the treatment of solid cancers”, said James Hussey, CEO at Seneca Therapeutics. SVV-001 is targeted immunotherapy that selectively kills cancer cells expressing the SVV-001’s receptor, TEM-8, and stimulates the immune system to attack the tumor. It consists of about 100 Union League members who actively invest in qualified, early-stage enterprises in the Greater Philadelphia and mid-Atlantic region as a means of growing the economy, retaining and attracting talent and fostering innovations that strengthen our civic infrastructure.
Classifications
AskAI Classifications
LabelsLinked Companies
